Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)
1,485.00
-2.00 (-0.13%)
Aug 12, 2026, 3:30 PM JST
TYO:2395 Revenue
Shin Nippon Biomedical Laboratories had revenue of 7.87B JPY in the quarter ending June 30, 2026, with 21.48% growth. This brings the company's revenue in the last twelve months to 33.92B, up 1.72% year-over-year. In the fiscal year ending March 31, 2026, Shin Nippon Biomedical Laboratories had annual revenue of 32.52B with 0.34% growth.
Revenue (ttm)
33.92B
Revenue Growth
+1.72%
P/S Ratio
1.83
Revenue / Employee
20.19M
Employees
1,680
Market Cap
61.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 32.52B | 111.00M | 0.34% |
| Mar 31, 2025 | 32.41B | 5.96B | 22.54% |
| Mar 31, 2024 | 26.45B | 1.36B | 5.42% |
| Mar 31, 2023 | 25.09B | 7.34B | 41.37% |
| Mar 31, 2022 | 17.75B | 2.64B | 17.46% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.62T |
| Otsuka Holdings | 2.62T |
| Chugai Pharmaceutical | 1.34T |
| HOYA Corporation | 983.64B |
| KYORIN Pharmaceutical | 125.68B |
| ASKA Pharmaceutical Holdings | 70.87B |
| Software Service | 46.49B |
| JCR Pharmaceuticals | 41.45B |